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The existence of an independent association between elevated triglyceride (TG) levels, cardiovascular (CV) risk and
mortality has been largely controversial. The main difficulty in isolating the effect of hypertriglyceridemia on CV risk is
the fact that elevated triglyceride levels are commonly associated with concomitant changes in high density
lipoprotein (HDL), low density lipoprotein (LDL) and other lipoproteins. As a result of this problem and in disregard of
the real biological role of TG, its significance as a plausible therapeutic target was unfoundedly underestimated for
many years. However, taking epidemiological data together, both moderate and severe hypertriglyceridaemia are
associated with a substantially increased long term total mortality and CV risk. Plasma TG levels partially reflect the
concentration of the triglyceride-carrying lipoproteins (TRL): very low density lipoprotein (VLDL), chylomicrons and their
remnants. Furthermore, hypertriglyceridemia commonly leads to reduction in HDL and increase in atherogenic small
dense LDL levels. TG may also stimulate atherogenesis by mechanisms, such excessive free fatty acids (FFA) release,
production of proinflammatory cytokines, fibrinogen, coagulation factors and impairment of fibrinolysis. Genetic studies
strongly support hypertriglyceridemia and high concentrations of TRL as causal risk factors for CV disease. The most
common forms of hypertriglyceridemia are related to overweight and sedentary life style, which in turn lead to insulin
resistance, metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM). Intensive lifestyle therapy is the main initial
treatment of hypertriglyceridemia. Statins are a cornerstone of the modern lipids-modifying therapy. If the primary goal
is to lower TG levels, fibrates (bezafibrate and fenofibrate for monotherapy, and in combination with statin; gemfibrozil
only for monotherapy) could be the preferable drugs. Also ezetimibe has mild positive effects in lowering TG. Initial
experience with en ezetimibe/fibrates combination seems promising. The recently released IMPROVE-IT Trial is the first
to prove that adding a non-statin drug (ezetimibe) to a statin lowers the risk of future CV events. In conclusion, the
classical clinical paradigm of lipids-modifying treatment should be changed and high TG should be recognized as an
important target for therapy in their own right. Hypertriglyceridemia should be treated.
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The independent association between elevated triglycerides
(TG), cardiovascular (CV) risk and mortality has been
largely controversial [1,2]. The main difficulty in isolating
the effect of hypertriglyceridemia on CV is the fact that ele-
vated TG levels are commonly associated with concomi-
tant changes in high density lipoprotein (HDL), low density
lipoprotein (LDL) and other lipoproteins. Although the
majority of studies found a substantial direct association* Correspondence: altenen@post.tau.ac.il
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article, unless otherwise stated.between TG and adverse outcomes [3-12], this association
sometimes became nonsignificant after multivariate adjust-
ment including other lipids and weight-related variables
[13-16]. For example, in the largest till now meta-analysis
[13], TG were associated with an increased risk of coronary
artery disease (CAD) after adjustment for age and sex, but
this association was abolished following an additional ad-
justment for HDL and non-HDL cholesterol. Correlations
with lower HDL cholesterol led to studies in which the au-
thors mathematically “adjusted” for these relationships,
suggesting that the HDL values could be invoked as more
likely contributors to risk than the TG themselves. As a re-
sult of these mathematical over-adjustment exercises andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cance of hypertriglyceridemia as a plausible therapeutic tar-
get was unfoundedly underestimated for many years.
However, epidemiology can be a poor guide to clinical de-
cisions and gives us only limited insight into the mecha-
nisms of atherogenesis and their relative importance in this
process. On the other hand, classification of elevated TG as
a major CV risk factor is clinically important since it deter-
mines whether high TG should be a target for therapy in
their own right.Hypertriglyceridemia and CV events
Serum TG are routinely measured under fasting condi-
tions to obtain more stable concentrations and to enable
the physician to calculate LDL cholesterol levels. In
addition, hypertriglyceridemia and postprandial lipide-
mia may affect the measurement of HDL cholesterol
and therefore the calculation of non-HDL cholesterol.
The NCEP ATP III arbitrarily divided fasting serum TG
into four different classes [17]. Classification of serum TG
levels greater than 150 mg/dl (1.7 mmol/liter) as elevated
is mainly based on large prospective observational studies.
However, the exact level at which serum TG start to con-
fer risk or become a marker for CV disease is unknown,
but it may be even lower than 150 mg/dl (1.7 mmol/liter)
[18]. Serum TG are higher in men and increase with age
in both sexes [19].
Very high TG (correspondent to severe hypertriglyc-
eridemia) are defined as serum TG> or = 500 mg/dl [3],
whereas the Endocrine Society Clinical Practice Guideline
[20] labeled as very severe hypertriglyceridemia serum
TG> or = 2000 mg/dl. The common view was that severe
and very severe hypertriglyceridemia increase the risk for
pancreatitis, whereas mild or moderate hypertriglyc-
eridemia may be a risk factor for CV disease [20]. In pa-
tients with very high TG levels – i.e. more than 25 mmol/
L - and patients with the familial chylomicronemia syn-
drome the risk for atherosclerosis is attenuated, perhaps
because their plasma lipoprotein particles are too large to
enter into the arterial intima [21] and [22]. However, there
are many indications that there is an increased risk of CV
disease in the marked or severe hypertriglyceridemia (fast-
ing triglyceride concentration exceeding 5.6 mmol/L and
11.2 mmol/L) as well [23,24]. Moreover, even in the prom-
inent old study of Assmann et al. [21] which emphasized a
J-shape for TG cardiovascular risk, TG above 800 mg/dl
were still associated with significantly greater risk than TG
less than 200 mg/dl, albeit it was decreased in comparison
to the 400–799 mg/dl levels.
Prospective studies have indicated that, compared with
fasting levels, nonfasting serum TG levels may be a better
or similar predictor of CV events in the general popula-
tion [25-29]. In a number of studies using standardizedmeals, greater CV risk was found to be associated with in-
creased hypertriglyceridemia [27,28].
The serum TG concentration is often more strongly
correlated with future CAD incidence in univariate ana-
lysis than is serum cholesterol. However, in multiple logis-
tic regression analysis, particularly when HDL cholesterol
is included, the strength of the apparent independent rela-
tionship between TG and CAD incidence is weakened
often to the point of insignificance in individual trials. The
erosion of the relationship between TG and CAD inci-
dence when HDL is included in multiple logistic regres-
sion analysis is to some extent an artifact of the greater
biological variation of TG concentrations compared with
HDL cholesterol. When allowance is made, TG can have
more predictive power than HDL [30]. Taking epidemio-
logical data together, both moderate and severe hypertri-
glyceridaemia are associated with a substantially increased
long term total mortality and CV risk.Triglycerides and atherogenesis
Currently LDL is considered as the major atherogenic
lipoprotein; however other lipoproteins size is of key im-
portance in determining whether particles can penetrate
the arterial wall. The plasma TG level represents in part
the concentration of the TRL: VLDL, chylomicrons and
their remnants. Although chylomicrons and probably
VLDL are both too large to penetrate the arterial wall,
their remnants are small enough to do this, and have
been demonstrated in human and animal atherosclerotic
plaques [31].
Physiologically TG are the densest form of calories
and serve as an important source of energy. Dietary TG
are assembled in the gut into chylomicrons. Their inter-
action with lipoprotein lipase (LpL) located on the lu-
minal surface of capillary endothelial cells leads to
liberation of free fatty acids from TG; free fatty acids are
able to traverse cell membranes. Only 50% of chylomi-
cron’s TG is estimated to be lost in this process, and the
remainder of the lipoprotein, called a chylomicron
remnant, contains lipids such as cholesteryl esters, reti-
nylesters, and apoB-48 [20].
VLDL particles are the main TG carrier in the circula-
tion, being produced by the liver, whereas the VLDL TG
content is derived from a variety of substrates including
lipoprotein TG and FFA. VLDLTG lose FFA by the action
of LpL as well, leading to production of VLDL remnants,
also referred to as intermediate-density lipoproteins (IDL),
and eventually to conversion to LDL. The concentration
of VLDL cholesterol and apolipoprotein B (apoB) is at
least 10 times higher than the corresponding chylomicron
concentration, even after consumption of a large amount
of fat [32-35]. These lipoproteins contain at least as much
cholesterol per particle as does LDL. TG itself is not a
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rich particles contributes to plaque development [36,37].
VLDL can be divided into large, TG -rich VLDL1 and
small, dense VLDL2. VLDL1 has a higher TG content
and exhibit abundant apolipoprotein CIII (apoCIII) and
apolipoprotein E [38,39].
An increase in TG-rich lipoproteins is commonly as-
sociated with a reduction in HDL and an increase in
small dense LDL levels. Hypertriglyceridemia stimulates
the enzymatic activity of cholesteryl ester transfer pro-
tein (CETP), which facilitates the transfer of TG from
TG -rich lipoproteins to HDL and LDL in exchange for
cholesteryl esters [40]. This leads to an increase in TG
content of HDL and LDL. TG -enriched HDL particles
are subject to increased catabolism; consequently, they
have a short plasma half-life. TG-enriched LDL particles
undergo subsequent hydrolysis via LpL or hepatic lipase,
thereby reducing LDL particle size. In addition, the dif-
ference in metabolic fate between VLDL1 and VLDL2
may also account for the increased formation of small
dense LDL. Kinetic data show that large TG -rich
VLDL1 particles yield small dense LDL whereas smaller
and denser VLDL2 particles are metabolized to normal
sized LDL [41].
TG may also stimulate atherogenesis by other mecha-
nisms, which include the production of proinflammatory
cytokines, fibrinogen and coagulation factors and im-
pairment of fibrinolysis. Therefore, their roles in athero-
genesis have a basic biological plausibility.
Hypertriglyceridemia as a major component of
atherogenic dyslipidemia related to insulin resistance, MS
and T2DM
Hypertriglyceridemia results from increased TG produc-
tion, or reduced TG catabolism, or both. Drugs such as
bile acid resins, estrogens, isotretinoin and steroids;
marked alcohol and fat ingestion in a susceptible patient;
or conditions such as poorly controlled diabetes or preg-
nancy can result in high triglyceride levels [42,43].
One of the reason for hypertriglyceridemia is alcohol
consumption. Alcohol intake increases hepatic fatty acid
synthesis and decreases fatty acid oxidation, with a net
effect to stimulate hepatic VLDL TG secretion. The ef-
fects of alcohol are dose-dependent [44,45]. However
the most common forms of hypertriglyceridemia are re-
lated to overweight and sedentary life style which leads
to insulin resistance. This setting of hypertriglyceridemia
is typical for MS and T2DM. The increase in TG pro-
duction may be due to excess FFA returning to the liver,
particularly in the setting of visceral obesity and insulin
resistance, and increased de novo TG production due to
hyperinsulinemia [46-48]. In hypertriglyceridemia, more
VLDL particles, as measured by apoB, and larger and
more TG- and apoC-III-enriched lipoproteins are found[49-51]. Hepatic insulin resistance may contribute to a
high production rate of VLDL because insulin reduces
apoB synthesis and VLDL secretion in the liver [52,53].
Although insulin resistance is associated with high triglyc-
erides, VLDL and TG concentrations can be similar in pa-
tients with widely divergent insulin sensitivity [54,55].
Hypertriglyceridemia, as one of the components of the
MS, is closely related to a constellation of metabolic risk
factors including a central distribution of adiposity or
visceral obesity, insulin resistance, impaired glucose tol-
erance, hypertension, and high TG and/or low HDL-C,
associated with an atherogenic, procoagulant, and proin-
flammatory state [56-64].
One could thought that TG are not directly involved in
the development of atherosclerotic lesions because FFA re-
leased from TG by lipoprotein lipase (LpL) act either as an
active energy source or stored energy reserve. However,
there are several plausible mechanisms by which FFA
might cause CV disease and death [65-71]. Furthermore,
an increase in plasma FFA leads to endothelial activation,
inflammation and thrombosis which may initiate early vas-
cular abnormalities that promote atherosclerosis [72-77].
Elevation of plasma FFA, in addition to producing periph-
eral and hepatic insulin resistance, also activates the proin-
flammatory NFκB pathway [73-84] resulting in increased
hepatic expression of several proinflammatory cytokines
including TNF-α, IL1-β, IL6, matrix metalloproteinases
and an increase in circulating MCP-1 [85-89], supporting
the notion that FFA is an important link between hyper-
triglyceridemia and the development of inflammatory
changes [90-99]. Moreover, elevated plasma FFA levels,
via producing insulin resistance and hyperinsulinemia,
promote a state of increased tendency for thrombosis
and decreased ability to fibrinolysis. Together, this sub-
stantially increases the risk for acute atherothrombotic
events [100-105].
Therefore, elevated FFA are not only an independent
risk factor for the development of T2DM, but also give
rise to metabolic derangements in organs such as the
liver and pancreas. Hypertriglyceridemia, FFAs overload
and lipid accumulation in non-adipose tissues influence
both insulin action and insulin secretion and are fre-
quently associated with IR and the development of
T2DM [106-109]. However the role of FFAs extends be-
yond their ability to induce or exacerbate insulin resist-
ance: they may contribute directly to the deterioration of
beta cell function that accompanies the development of
diabetes [109-113]. Both acute stimulatory and long-
term detrimental effects of FFAs overloading on pan-
creatic beta-cell have long been recognized. Chronic
exposure of the pancreatic beta-cell to FFA results in
desensitization and suppression of secretion (lipotoxi-
city) as a consequence of TG accumulation in the islets
of Langerhans [109].
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lipids metabolism play a pivotal role in the pathophysi-
ology of diabetes, it was suggested to drop the adjective
“mellitus” from diabetes and then to consider the intro-
duction of a new adjective “lipidus” or “lipomellitus”
[114] (Figure 1).
TG and HDL
Raised TG concentrations are strongly associated with low
concentrations of HDL cholesterol, and the past 25 years
have been dominated by HDL research, with less focus on
TG. The hypothesis that HDL is protective against athero-
sclerosis was supported by a series of animal studies in the
1980s and 1990s. Badimon and colleagues [115] infused
HDL into rabbits and reported inhibition of atheroscler-
osis. Rubin and colleagues [116] showed that mice overex-
pressing the major HDL protein apolipoprotein A-I
(apoA-I) are protected from atherosclerosis. Viral overex-
pression of apoA-I in mice with pre-existing atheroscler-
osis resulted in regression of pre-existing atherosclerotic
disease [117]. These preclinical data matched the epi-
demiological data and strongly reinforced the HDL hy-
pothesis, making HDL a major target for novel therapeutic
approaches to decrease atherosclerosis.
Consequently, HDL has long been regarded as the
“good” lipoprotein because epidemiological and clinical
studies have identified an inverse association between
HDL concentration and CV disease [118,119]. The most
important antiatherogenic function of HDL is reverseFigure 1 Hypertriglyceridemia, FFAs overload and lipid accumulation
in the pathogenesis of T2DM, mainly via insulin resistance and pancrcholesterol transport [120]. HDL also exhibits other po-
tential cardioprotective functions such as anti-oxidative,
anti-inflammatory and endothelium-dependent vasodila-
tory effects [121-123].
However, a failing initial experience with CETP inhibi-
tors has been most problematic for the HDL hypothesis
[124-126]. Moreover, reports from several randomized
clinical trials of HDL-raising drugs have failed to show a
reduction in CV events. Particularly, two recent trials of
niacin (using extended-release niacin; AIM-HIGH [127]
and HPS2-THRIVE [128]) were done on the background
of statin therapy and were primarily designed to show
the benefit of the HDL-raising effects of niacin. Neither
trial met its primary endpoint and niacin failed to reduce
cardiovascular events in both trials. Based on this,
extended-release niacin added to a statin in patients with
reasonably controlled LDL-C concentrations does not
confer a cardiovascular benefit despite an increase in
HDL-C concentrations. As a result, niacin at present
should not be considered a therapeutic option for raising
HDL-C concentrations.
In accordance with the HDL function hypothesis, it is
not HDL cholesterol itself that has a causal relation to
atheroprotection, but rather HDL function, which can-
not be reliably estimated through the simple measure-
ment of HDL-C [129,130].
Interesting lessons could be derived from the Bezafibrate
Infarction Prevention (BIP) study with bezafibrate and ba-
sically low HDL in all patients: despite of a significantin nonadipose tissues (so called lipotoxicity) are the key events
eatic beta-cell failure.
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However, the benefit of bezafibrate in the subgroup of pa-
tients with high TG levels was extremely impressive.
Additional challenges to the HDL hypothesis are driven
by data derived from human genetic studies and ran-
domized controlled trials. Taken together, genetic studies
strongly support the theory that high concentrations of
TG-rich lipoproteins or remnant cholesterol are causal risk
factors for cardiovascular disease and all-cause mortality
[2,131-138], and that low HDL cholesterol is probably an
innocent bystander. Low HDL cholesterol might merely be
a long-term marker of raised TG and remnant cholesterol.
Alternatively, HDL cholesterol might be a marker of cardio-
vascular health but is non-causal in the atherogenesis [130].
Management of hypertriglyceridemia
Intensive lifestyle therapy, including dietary counseling
to achieve appropriate diet composition, physical activ-
ity, and a program to achieve weight reduction in over-
weight and obese individuals are the main initial
treatment of hypertriglyceridemia and described else-
where [20,139-141].
Elevated levels of TG (and TG -rich lipoproteins) are
increasingly being recognized as treatment targets to
lower CV risk in certain patient subgroups, including in-
dividuals receiving statins – a cornerstone of the modern
lipids-modifying therapy. The choice of statin should de-
pend on the needs of the individual patient. In this con-
text, the potential benefits of pitavastatin versus other
statins in the treatment of patients with dyslipidemia
and insulin resistance, metabolic syndrome or type 2
diabetes should be emphasized [142-144]. Moreover, al-
though some statins are associated with increased
haemoglobin A1C levels in patients receiving intensive
but not moderate therapy, pitavastatin has demonstrated
neutral or even favourable effects on glucose control in
patients with and without T2DM or MS [145,146]. How-
ever, intensive statin therapy with the most potent sta-
tins (atorvastatin, rosuvastatin and even pitavastatin)
does not completely eliminate the residual cardiovascu-
lar risk associated with high TG.
At present the number of drug classes (fibrates, niacin,
n-3 fatty acids, CETP –inhibitors, ezetimibe, glitazars,
etc.) alone or in combination with statins have been con-
sidered as treatment options in patients with moderate to
severe TG levels. However, many of these agents are cur-
rently under serious concerns: niacin after the negative
AIM HIGH study and HPS-2 THRIVE trial results
[127,128]. CETP inhibitors and glitazars are still in contro-
versial developments and not available for clinical use.
Supplemental n-3 polyunsaturated fatty acids (PUFAs),
mainly eicosapentaenoic acid and docosahexaenoic acid,
are well known to reduce hypertriglyceridemia [147]. In
addition to hypotriglyceridemic effects, omega-3 fatty acidsmay attenuate inflammation, improve endothelial function
and reduce thrombus formation [148,149]. However, re-
cent clinical outcome trials with have failed to show sig-
nificant CV benefits in high risk subjects [150-152].
Ezetimibe inhibits intestinal cholesterol absorption and
primarily lowers LDL cholesterol via the Niemann-Pick
C1- Like 1 protein. Ezetimibe has slight positive effects in
lowering plasma fasting TG (8%) [153]. In addition, ezeti-
mibe reduces the cholesterol content of both fasting and
postprandial TG -rich lipoproteins, thereby lowering the
concentrations of atherogenic remnant particles [154].
Initial experience of ezetimibe/fibrates combination seems
promising [155,156]. The recently released IMPROVE-
IT (IMProved Reduction of Outcomes: Vytorin Efficacy
International Trial) is the first to prove that adding a non-
statin drug (ezetimibe) to a statin (simvastatin) lowers the
risk of future CV events. Compared to patients with CAD
on simvastatin plus a placebo, those on both simvastatin
and ezetimibe, had a 6.4% lower risk of all CV events, a
14% lower risk of all heart attacks, a 14% lower risk of
stroke, and a 21% lower risk of ischemic stroke. Deaths
from CV disease were statistically the same in both groups.
Patients were followed an average of approximately six
years, and some as long as 8.5 years. Approximately 2 pa-
tients out of every 100 patients treated for 7 years avoided
a heart attack or stroke. The Number Needed to Treat
was = 50 [157]. This result represents a strong evidence-
based support for the concept of the benefits of an appro-
priate statin/non-statin combination therapy.
Fibrates enhance the oxidation of fatty acids in liver and
muscle and reduce the rate of hepatic lipogenesis, thereby
reducing secretion of VLDLTG. The increased uptake of t
TG -derived fatty acids in muscle cells results from an in-
crease in LpL activity in adjacent capillaries and a decrease
in the apolipoprotein CIII (apo CIII) concentration medi-
ated transcriptionally by peroxisome proliferator activated
receptor (PPAR) alpha. The decrease in apolipoprotein
CIII reduces the inhibition of LpL activity. The enhanced
catabolism of VLDL generates surface remnants, which
are transferred to HDL. HDL concentrations are further
augmented by an increase in PPAR alpha - mediated tran-
scription of apoAI) and apo AII. Ultimately, the rate of
HDL-mediated reverse cholesterol transport may increase.
Fibrates activate PPAR alpha, which binds to a PPAR
alpha response element in conjunction with the retinoid X
receptor. Other effects of fibrates include an increase in
the size of LDL particles, increased removal of LDL, and a
reduction in the levels of plasminogen activator inhibitor
type I [158-162].
From a clinical point of view, in all available 5 ran-
domized control trials the beneficial effects of major
fibrates (gemfibrozil, fenofibrate, bezafibrate) were clearly
demonstrated and were highly significant in patients with
hypertriglyceridemia [163-168].
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ing 4726 patients, a 35% relative risk reduction in CV
events was observed compared with a non- significant
6% reduction in those without dyslipidemia [169]. Meta-
analysis performed in a so called "general population"
[170] reflecting a blend of effects in patients with and
without atherogenic dyslipidemia - a mean diluted effect
of fibrate therapy was reduced, producing only 13% RR
reduction for coronary events (p < 0.0001). Therefore, in
patients with high triglycerides, fibrates - either as
monotherapy or combined with statins - are consistently
associated with reduced risk of cardiovascular events
[171,172]. Therefore, if the primary goal is to lower TG
levels, fibrates (bezafibrate and fenofibrate for monother-
apy and combination with statin; gemfibrozil only for
monotherapy) now are the preferable drugs [173,174].Conclusions
Taking epidemiological data together, both moderate and
severe hypertriglyceridaemia are associated with a sub-
stantially increased long term total mortality and CV dis-
ease risk. The plasma TG level represents in part the
concentration of the TRL: VLDL, chylomicrons and their
remnants. TG may also stimulate atherogenesis by other
mechanisms, which include the production of proinflam-
matory cytokines, fibrinogen and coagulation factors and
impairment of fibrinolysis. The most common forms of
hypertriglyceridemia are related to overweight and seden-
tary life style which leads to insulin resistance and typical
for MS and T2DM. Therefore, the role of hypertriglyc-
eridemia in atherogenesis has a multifactorial biological
plausibility. Also genetic studies strongly support the the-
ory that hypertriglyceridemia and high concentrations of
TRL are causal risk factors for CV disease and mortality.
Intensive lifestyle therapy is the main initial treatment of
hypertriglyceridemia. If the primary goal is to lower TG
levels, fibrates (bezafibrate and fenofibrate for monotherapy
and combination with statin; gemfibrozil only for mono-
therapy) now are the preferable drugs. Finally, the clinical
paradigm of lipids-modifying treatment should be changed
and high TG should be recognized as an important target
for therapy in their own right. Hypertriglyceridemia should
be treated.
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